The Effect of Omega 3 on 25 Hydroxyvitamin D

The Effect of Omega 3 Supplementations on Serum 25 Hydroxyvitamin D Levels

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04174625

Acronym

n-3FAon25OHD

Enrollment

Registered

2019-11-22

Start date

2020-11-25

Completion date

2021-12-15

Last updated

2022-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

25-hydroxyvitamin D Levels

Keywords

omega 3, 25 hydroxyvitamin D, 25OHD, Vitamin D

Brief summary

The effect of omega 3 fatty acid on serum 25-hydroxyvitamin D levels.

Detailed description

No data are available on the effect of omega 3 on serum 25-hydroxyvitamin D levels in Jordanian men and women. This study was designed to investigate whether omega 3 supplementation has a potential effect on the reducing of serum 25-hydroxyvitamin D levels. This randomized, placebo-controlled clinical trial (RCT) was designed to evaluate 300 mg omega-3FA daily for 2 months on serum levels of 25-hydroxyvitamin D levels. This RCT will be conducted on 80 to 90 Jordanian men and women aged 22 to 66 years. Baseline and follow-up levels for 25-hydroxyvitamin D (25OHD), parathyroid hormone (PTH), calcium, phosphate, liver and kidney functions will be assayed.

Interventions

DIETARY_SUPPLEMENTDietary Supplement: Omega3-FA

Dietary Supplement: Omega3-FA 300 mg of omega3-FA once daily for 8 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

22 Years to 66 Years

Healthy volunteers

Yes

Inclusion criteria

Age ≥18 years old Male and female Jordanian ASU students and employees who live in Amman. Informed written consent from the participant prior to the start of the study. a serum 25(OH)D concentration between 10 and 70 ng/mL.

Exclusion criteria

Any eligiable subject refuses to apply with informed written consent before the start of the study. Men or women previously diagnosed with chronic diseases, including kidney disease or GIT problems. Who are receiving vitamin D3 supplements (3 months before the start of the study) . Pregnants,Breastfeeding females ,Females using hormonal contraceptives

Design outcomes

Primary

Measure	Time frame	Description
serum concentrations of 25-hydroxyvitamin D	8 weeks	ng/ml
serum concentrations of PTH	8 weeks	pg/mL

Other

Measure	Time frame	Description
serum concentration of calcium	8 weeks	mg/dl
serum concentration of phosphate	8 weeks	mg/dl
serum ALT	8 weeks	U/L
Serum urea	8 weeks	mg/dL

Countries

Jordan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026